noribogaine and Opioid-Related-Disorders

Topics: Animals; Behavior, Animal; Brain; Corticosterone; Dopamine; Humans; Ibogaine; Opioid-Related Disorders; Serotonin

The aim of this study was to switch patients established on methadone opioid substitution therapy (OST) to morphine over 1 week. Subjects established on daily methadone OST (mean dose 60 mg/day) were switched to morphine slow-release capsules, dosed at 4× the previous total daily methadone dose, for 6 days, then given morphine syrup dosed q3h. All 27 subjects enrolled in this study completed the switch from methadone to morphine. Opioid withdrawal symptoms (OWS) peaked within 12-24 hours of starting morphine, and 24/27 subjects required higher daily morphine doses (mean 5.2× multiple). Pharmacokinetic evaluation showed that 91% of methadone was cleared during this time, with a mean elimination half-life of 59 hours. The most frequent treatment-emergent non-OWS adverse events were headache, nausea, constipation, and neck pain. The method described here appears to be a safe and acceptable approach to switch subjects from methadone to morphine.

Topics: Adult; Analgesics, Opioid; Double-Blind Method; Drug Substitution; Female; Headache; Humans; Ibogaine; Male; Methadone; Morphine; Nausea; Opiate Substitution Treatment; Opioid-Related Disorders; Treatment Outcome

Topics: Adult; Area Under Curve; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Heart Rate; Humans; Ibogaine; Long QT Syndrome; Male; Methadone; Narcotics; Opiate Substitution Treatment; Opioid-Related Disorders; Substance Withdrawal Syndrome